Léon, Catherine <br/><br/>
Romiplostim administration shows reduced megakaryocyte response-capacity and increased myelofibrosis in a mouse model of MYH9-RD.  [electronic resource] 

 -  Blood  Apr 2012 
 - 3333-41 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood-2011-08-373811  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Bleeding Time<br/>Blood Platelets--drug effects<br/>Bone Marrow--metabolism<br/>Embolism--chemically induced<br/>Factor IX--metabolism<br/>Factor V--metabolism<br/>Female<br/>Leukocyte Count<br/>Lung--pathology<br/>Male<br/>Megakaryocytes--drug effects<br/>Membrane Glycoproteins--metabolism<br/>Mice<br/>Mice, Inbred C57BL<br/>Mice, Knockout<br/>Myosin Heavy Chains<br/>Nonmuscle Myosin Type IIA--genetics<br/>P-Selectin--metabolism<br/>Platelet Count<br/>Platelet Glycoprotein GPIIb-IIIa Complex--metabolism<br/>Platelet Membrane Glycoproteins--metabolism<br/>Primary Myelofibrosis--metabolism<br/>Receptors, Fc--administration & dosage<br/>Recombinant Fusion Proteins--administration & dosage<br/>Reticulin--metabolism<br/>Spleen--cytology<br/>Thrombocytopenia--genetics<br/>Thrombopoietin--administration & dosage